# NCT01080391 (NCT01080391)

> Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01080391
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Amgen
- Conditions: Relapsed Multiple Myeloma
- Interventions: Dexamethasone; Lenalidomide; Carfilzomib
- Enrollment: 792
- Primary outcome: Progression-free Survival (PFS)

## Indexed commentary on NCT01080391 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01080391